The novel synthetic receptors γ-TCRγδ targeting PD-L1 demonstrated superior antitumor activities in both in vitro and in vivo solid tumor models, such as NSCLC and melanoma, supporting the strategy of inhibiting the PD1/PD-L1 axis to treat solid tumors. Here, CD274 is linked to melanoma.